S
EVERAL constituents of blood have been considered in the pathogenesis of delayed arterial narrowing after subarachnoid hemorrhage (SAH), most notably the breakdown products of lysing erythrocytes. Oxyhemoglobin is a potent vasoconstrictor for cerebral arterial segments in vitro ~~9 and causes calcium influx and morphological changes in smoothmuscle cells in culture. 9 Chronic application of hemoglobin to cerebral arteries produces delayed arterial narrowing and ultrastructural changes consistent with vasospasm. ' 7 The mechanism by which hemoglobin produces delayed arterial narrowing has not been determined. In addition to direct vasoconstriction, hemoglobin and its metabolites may produce cell injury through the generation of cytotoxic superoxide free oxygen radicals with an associated cascade of lipid peroxidation, z4 The Haber-Weiss reaction resulting in singlet oxygen formation ~ is catalyzed by the presence of free ferric ion, ~ 1.2o which has been implicated in several other types of tissue injury/'=' 4 To investigate the role of the ferric ion in cerebral vasospasm, we applied deferoxamine, a selective ferric chelating agent and antioxidant, in a rat femoral artery model. The rat femoral artery model:' enables the localized application of agents directly to the site of interest, thus minimizing extraneous effects related to systemic distribution of the drug. Because deferoxamine does not chelate heme-associated iron,~5 inhibition of vasospasm by deferoxamine would indirectly implicate free ferric iron rather than hemoglobin in the pathogenesis of delayed arterial narrowing after SAH.
Materials and Methods
Thirty male Sprague-Dawley rats, each weighing 450 to 500 gm, were used in this study. All procedures were performed using protocols approved by the Animal Care Committee of the Seattle Veterans Administration Medical Center. Rats were randomly assigned to six experimental groups as shown in Table 1 , anesthetized with intraperitoneal pentobarbital sodium (50 mg/kg), and allowed to breathe spontaneously. The femoral artery model for vasospasm utilized in our laboratory has been described previously. -~ Using sterile microsurgical technique, 1-cm segments of both femoral arteries and veins were exposed in the inguinal region. In four groups of five rats each (Groups A to D), various concentrations (1, 5, 10, or 25 mg) of deferoxamine (Desferal) were reconstituted in 30 ul normal saline and mixed thoroughly with I ml fresh nonheparinized fern- A deferoxamine 1 mg/ml in 0.1 ml whole blood 0.1 mg B deferoxamine 5 mg/ml in 0.1 ml whole blood 0.5 rng C deferoxamine 10 mg/ml in 0.1 rnl whole blood 1.0 mg D deferoxamine 25 mg/ml in 0.1 ml whole blood 2.5 mg E deferoxamine 10 mg + FeCh 4 mg/ml in 0.1 1.0 mg ml whole blood F platelet-rich plasma O. 1 ml 0 oral venous blood. A 0.l-ml aliquot of the deferoxamine-blood mixture was immediately applied to the adventitial surface of the left femoral arteu and covered with a cylindrical Silastic cuff. Whole blood and saline were similarly applied to the right (control) femoral artery in all animals. In five rats (Group E), deferoxamine (10 mg in 30 #1 saline) was saturated with excess ferric ion (ferric chloride 4 rag) for 30 minutes before being mixed with blood and applied to the artery. In an additional five control animals (Group F), erythrocytefree autologous platelet-rich plasma was prepared as described previously ~7 and applied to the femoral adventitia. Seven days after the application of blood, the rats were anesthetized with i ntraperitoneal pentobarbital sodium and the femoral arteries were perfusion-fixed in s#u at physiological mean arterial pressure via a cardiac cannula with 200 ml of 0.03 M phosphate-buffered Ringer's solution, followed by 200 ml of 4% paraformaldehyde and 1% of glutaraldehyde in phosphate buffer (pH 7.4). After perfusion-fixation, 10-mm segments of both femoral arteries encompassed by the Silastic cuff were harvested, placed in the perfusion fixative for an additional 4 hours, and stored overnight in cold (4"C) 0.03 M phosphate-buffered solution. The vessels were dehydrated in graded ethanols, embedded in ethyl methacrylate, sectioned at 3 ~m thickness, mounted on glass slides, and stained with hematoxylin and eosin.
The cross-sectional areas of vessel lumen were calculated on five randomly selected microscopic sections of each artery, on digitized video images, magnified x 52, using an automated image-analysis system.* Previous work in our laboratory substantiated the accuracy of such measurements by comparison with stereological analysis. ~ The luminal areas for each group were expressed as the mean _+ standard error of the mean, and differences between experimental and control vessels were assessed by Student's t-test, with p values less than 0.05 considered significant.
Graded standard concentrations of ferric chloride were prepared in a solution of 135 mM NaCI, 5 mM KCI, 25 mM NaHCO3, 0.4 mM NaH2PO4, and 10 mM * Bioquant System IV image-analysis system manufactured by R & M Biornelrics, Nashville, Tennessee.
T. ttarada and M. R. Mayberg HEPES (pH 7.4). After reduction wilh ascorbic acid, standard curves for free Fe +++ were measured as its chromagen complex using spectrophotometry.t To determine in vilro Fe +++ release and chelation by deferoxamine in whole blood over time, fresh human blood was anticoagulated with heparin, 1-ml aliquots were mixed with deferoxamine at concentrations ranging from 0.1 to t0 mg/ml, and samples were incubated under aseptic conditions at 37~ At daily intervals from 1 through 7 days, samples were centrifuged and the supernatant analyzed for free ferric ion using spectrophotometry as above.
Results

In Vivo Analysis'
At the time of blood application, there was no discernible difference in coagulation or clot appearance among the various groups. Similarly, the contents of the Silastic cuff were indistinguishable among groups at sacrifice, with the exception of absent heme staining in the platelet-rich plasma group.
By light microscopy, chronic perivascular application of platelet-rich plasma (Group F) produced no change in arterial diameter or histological changes in vessel wall. Control femoral arteries exposed to whole blood uniformly demonstrated a spectrum of histological changes associated with vasospasm, including a marked reduction in luminal diameter, apparent thickening of the vessel wall, smooth-muscle vacuoles, and endothelial-cell distortion by convolution of the adjacent internal elastic lamina. Minimal histological changes and luminal narrowing were seen in arteries exposed to the blood containing deferoxamine at concentrations of 5 to 25 mg/ml (Groups B, C, and D). In animals treated with deferoxamine at a concentration of 1 mg/ml (Group A) or 10 mg/ml plus ferric chloride (Group E), moderate degrees of pathological change with narrowing of luminal diameter were observed.
A morphometric analysis of luminal cross-sectional areas of vessels for each group is shown in Fig. 1 . Compared to platelet-rich plasma, control femoral arteries exposed to whole blood or blood with deferoxamine at a concentration of 1 mg/ml showed a 63% to 77% reduction in luminal area. At 5 or 10 mg/ml, deferoxamine significantly inhibited arterial narrowing in an apparent dose-dependent manner (26% and 16% reductions in luminal area, respectively). Vessels treated with 25 mg/ml of deferoxamine showed no luminal narrowing. Saturation of deferoxamine with additional ferric ion prior to application markedly attenuated its protective effect (58% reduction in luminal area).
In Vitro Ana/ysis
The effect over time of defcroxamine on free Fe +++ in the supernatant of anticoagulated blood is shown in t Spectrophotometric analyzer, Model 717, manufactured by Boehringer Mannheim/Hitachi, Houston, Texas. Table 1 . Fig. 2 . Untreated heparinized blood released ferric ion into plasma beginning on Day 3 of incubation with rapid increases to concentrations of 25 rag/liter observed between Days 5 and 7. Deferoxamine at concentrations between 1 and 10 ml/mg produced dose-dependent reduction in free Fe +++ during this period.
I n h i b i t i o
n o f v a s o s p a s m by d e f e r o x a m i n
Discussion
Considerable evidence has implicated substances in the erythrocyte fraction of whole blood as the causative agent(s) for cerebral vasospasm. 7"~3''72~ 23 Red cell lysis in cerebrospinal fluid is at a maximum during the period of clinical vasospasm (5 to 8 days) and serum from incubated thrombus was most vasoactive during this period. 3 The intracisternal injection of blood lacking erythrocytes did not produce angiographic or structural narrowing, 7 and extracts of lysed erythrocytes, ~''~ oxyhemoglobin, ~~ or bilirubin ~' produced sustained contraction in cerebral vessels. Fox s noted that topical application of ferric (but not ferrous) iron produced mild immediate vasoconstriction in vivo. In our laboratory, selective chronic exposure of pig middle cerebral artery or rat femoral artery to washed erythrocytes or hemoglobin produced arterial narrowing comparable to whole blood, whereas vessels treated with leukocytes, platelet-rich plasma, or erythrocyte membranes were indistinguishable from controls. 172~
Lipid Peroxidation and I/asospasm
The mechanism by which hemoglobin produces vasoconstriction and structural changes in arterial wall has not been determined. Oxyhemoglobin is a potent vasoconstrictor for cerebral arteries ~' and inhibits the release of endothelium-derived relaxing factor. J~ Isolated smooth-muscle cells accumulate intracellular calcium and exhibit profound ultrastructural changes after   FIG. 2 . Graph depicting release of ferric ion over time from incubated heparinized human blood in vitro. Blood samples were mixed at onset of incubation with deferoxamine at doses ranging from 0. l to 10 mg/ml (see text).
exposure to oxyhemoglobin but not to methemoglobin2 Alternatively, hemoglobin catabolites may mediate smooth-muscle cell injury via iron-catalyzed lipid peroxidation. In extracellular fluid, (ferrous) hemoglobin is rapidly auto-oxidized to (ferric) methemoglobin and undergoes subsequent degradation to bilirubin, globin, and elemental iron. 2~ Although the heine portion of oxyhemoglobin is hydrophobic, random fluctuations of the heine pocket may allow access of water and heine oxygenase to the heine moiety, resulting in the formation of methemoglobin and/or release of free iron. ~ Oxyhemoglobin and free ferric ion catalyze the conversion of superoxide to hydroxy radicals and singlet oxygen, which initiate a cascade of eytotoxic lipid peroxidation involving unsaturated fatty acids in the cell membrane. 4~ L2o Endogenous intracellular antioxidants normally limit this reaction, but can be overwhelmed in the setting of high concentrations of ferric ion. 4~~ Free radical-mediated cytotoxicity has been implicated in a number of pathological processes ~~H including arterial injury in atherogenesis. Sano, et al.] 4 have summarized the potential role of lipid peroxidation in vasospasm after SAH.
Deferoxamine is a bacterial siderophore isolated from Streptomyces pilostts: it selectively chelates free ferric ion but has no effect upon iron bound to proteins such as heine or transferrin. 4t~ In addition, deferoxamine renders iron unreactive to free radical-generating reactions that damage biomolecules and tissues. ~.~-~.2~ In experimental models of cold-induced brain edema, ~4 postischemic reperfusion injury] and skin necrosis] deferoxamine effectively limited tissue injury, presumably by this mechanism. In a rabbit model of vasospasm, Vollmer, et al., 26 demonstrated a reduction in arterial narrowing after treatment with subcutaneous deferoxamine.
Ferric Ion
In the current study, deferoxamine provided a significant dose-dependent reduction in arterial narrowing and associated arterial wall histological changes in rat femoral arteries exposed to whole blood for 7 days. Contralateral arteries exposed to blood showed typical arterial narrowing, suggesting that the deferoxamine was acting locally at the site of application. Deferoxamine chelates ferric iron at a ratio of 100 to 8.5, by weight (10 mg of deferoxamine chelates ferric iron contained in 4 mg FeCI)). In this experiment, presaturation of deferoxamine with excess iron prior to mixing with blood according to these ratios attenuated the protective effect observed for deferoxamine alone. In vilro analysis confirmed that deferoxamine selectively chelated ferric ion, but not free calcium. The time course of ferric ion release from anticoagulated blood in vitro coincided with that of clinical vasospasm. In addition, chelation of ferric ion released from lysing erythrocytes was maximum at concentrations of the drug that were most effective in vivo. These data suggest that ferric ion may in part mediate mechanisms that cause chronic arterial narrowing after SAH.
The specific fate of free iron in perivascular thrombus after SAH is unknown. In vitro studies in this experiment showed release of significant amounts of ferric ion in a time-dependent manner, which corresponded to the temporal course of cerebral vasospasm. Recent work in our laboratory has shown similar release kinetics for oxyhemoglobin from lysing thrombus in vitro, with progressive accumulation of methemoglobin (unpublished data). These data suggest that oxyhemoglobin release from lysing erythrocytes, the liberation of free ferric ion, and oxidation to methemoglobin occur during the critical period of delayed arterial narrowing. The immediate role of ferric ion in vasospasm might best be demonstrated by its direct application to the artery wall. However, ferric ion in solution is rapidly oxidized to ferrous ion within 30 minutes, thereby preventing the prolonged exposure that may be necessary for the development of delayed arterial narrowing. In this regard, acute topical application of ferric ion to cerebral arteries produced only mild vasoconstriction, whereas ferrous iron solutions caused no narrowing. ~ Although the effective local concentration of deferoxamine used in this experiment was probably greater than that employed in other settings, ~'2~4 it is unlikely that the protective effect was due to other unspecified mechanisms of action. In addition, the response of rat femoral arteries to perivascular agents enclosed in a Silastic cuff may not necessarily correspond to mechanisms occurring in cerebral arteries exposed to subarachnoid blood. Further investigations are necessary to determine whether ferric ion causes arterial narrowing through direct toxic effect or via mechanisms such as lipid peroxidation.
